Remus Pharmaceuticals Limited — Investor Meet, 15-11-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Remus Pharma's H1 FY2026 standalone results were strong: Revenue 47 Cr (+24% YoY), EBITDA 15 Cr (+31% YoY, 31.56% margin), PAT 12 Cr (+31% YoY). Consolidated revenue hit 400 Cr (+47% YoY), EBITDA 27 Cr (+28% YoY, 6.75% margin), PAT 22 Cr (+21% YoY).

Management highlighted global expansion and fast product launches. B2C business grew to 13% (from 4%), targeting 20-25% in 1.5 years for margin growth. Consolidated margins reflect the US subsidiary's high-volume, low-margin RLD distribution (80% of revenue). The company aims for 8-10% consolidated PAT margins by increasing B2C and emerging market share. New markets like Kenya, Chile, and Dominican Republic are planned, with 3 new subsidiaries this fiscal year. Confident outlook.